S-Ethylthiotrifluoroacetate Enhancement of the Immune Response to Halothane in the Guinea Pig
Halothane hepatitis appears to be a hypersensitivity reaction to neoantigens formed when halothane reactive intermediates covalently bind to liver proteins. Production of an animal model for halothane hepatitis has been largely unsuccessful, possibly due to inadequate cytochrome P-450 mediated biotransformation of halothane to reactive intermediates. S-ethylthiotrifluoroacetate (SETFA) reacts rapidly and efficiently with protein lysine groups to form trifluoroacetylated proteins. The advantage to this procedure is that cytochrome P-450 mediated activation is not required. Male Hartley guinea pigs (600–700 g) were injected (ip) with SETFA (50 ml) emulsified in an adjuvant-mycobacterial protein mixture. Subsequent exposure to halothane produced a 10x increase in anti-trifluoro acetylated albumin antibody response compared to controls, as well as centrilobular lesions consistent with halothane toxicity. Western-type immunoblot analysis demonstrated three unique antigen bands in microsomal fractions from SETFA-treated guinea pigs. The adjuvant-mycobacterial mixture alone caused only minor liver lesions and minimal immune response. SETFA may be effective for producing the reactive intermediate of halothane metabolism, bypassing the need to induce atypical halothane metabolism to produce an im munopathological response.
KeywordsHalothane Hepatitis Mycobacterial Protein Leukocytic Infiltrate Halothane Exposure Halothane Metabolism
Unable to display preview. Download preview PDF.
- Brown, A.P., Hastings, K.L., Gandolfi, A.J. and Brendel, K. Covalent binding of halothane metabolite and neoantigen production in guinea pig liver slices. IV International Symposium on Biological Reactive Intermediates, Tucson, January, 1990.Google Scholar
- Hastings, K.L., Schuman, S., Brown, A.P., Hubbard, A.K. and Gandolfi, A.J. (1990). Examination of guinea pig liver for halothane-associated neoantigen production in animals exposed to halothane, enflurane, or isoflurane. Anesthesiology, submitted.Google Scholar
- Kenna, J.G., Satoh, H., Christ, D.D. and Pohl, L.R. (1988). Metabolic basis for a drug hypersensitivity: Antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J. Pharmacol. Exp. Therap. 245, 1103 - 1109.Google Scholar
- Lunam, C.A., Cousins, M.S. and Hall, P.M. (1985). Guinea pig model of halothane-associated hepatotoxicity in the absence of enzyme induction and hypoxia. J. Pharmacol. Exp. Therap. 232, 802 - 809.Google Scholar
- Lunam, C.A., Hall, P.M. and Cousins, M.J. (1989). The pathology of halothane hepatotoxicity in a guinea pig model: A comparison with human halothane hepatitis. Br. J. Exp. Path. 70, 533 - 541.Google Scholar
- Satoh, H., Gillette, J.R., Takemura, T., Ferrans, V.J., Jelenich, S.E., Kenna, J.G., Neuberger, J. and Pohl, L.R. (1986). Investigation of the immunological basis of halothane-induced hepatotoxicity. In, Biological Reactive Intermediates-HI, (Ed. J.J. Kocsis, D.J. JoHow, C.M. Witmer, J.0. Nelson, and R. Snyder), pp. 657 - 673. Plenum Press, New York.Google Scholar
- Satoh, H., Fukuda, Y., Anderson, D.K., Ferrans, V.J., Gillette, J.R. and Pohl, L.R. (1987). Immunological studies on the mechanism of halothane-induced hepatotoxicity: Immunohistochemical evidence of trifluoroacetylated hepatocytes. J. Pharmacol. Exp. Therap. 233, 857 - 862.Google Scholar